Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
|Videos|May 10, 2011
Jamie Myers Describes the Design of Her CRCI Study
Author(s)Jamie Myers, PhD, RN
Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study
Advertisement
Jamie Myers, PhD, RN, AOCN® from the School of Nursing at the University of Kansas Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study
Advertisement
Related to this article
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5